FDA Approves WINREVAIR for Pulmonary Arterial Hypertension Based on Phase 3 Study
The FDA has approved an updated indication for WINREVAIR (sotatercept-csrk) based on the Phase 3 ZENITH study, showing it significantly reduces the risk of clinical worsening and improves exercise capacity in adults with PAH, expanding its use in treatment.